Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy

References

• Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung environment and pseudomonas aeruginosa infection. BMC Pulm Med. 2016;16(1):174. doi:10.1186/s12890-016-0339-527919253
   PubMed Web of Science ®Google Scholar
• Ferec C, Cutting GR. Assessing the disease-liability of mutations in CFTR. Cold Spring Harb Perspect Med. 2012;2(12):a009480. doi:10.1101/cshperspect.a00948023209179
   PubMed Web of Science ®Google Scholar
• Shwachman H, Holsclaw DS. Complications of cystic fibrosis. N Engl J Med. 1969;281:500–501. doi:10.1056/NEJM1969082828109105796970
   PubMed Web of Science ®Google Scholar
• Tsui LC, Buchwald M, Barker D, et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science. 1985;230:1054–1057. doi:10.1126/science.29979312997931
   PubMed Web of Science ®Google Scholar
• Kerem B-S, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245:1073–1080. doi:10.1126/science.25704602570460
   PubMed Web of Science ®Google Scholar
• Rommens JM, Iannuzzi MC, Kerem B-S, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245:1059–1065. doi:10.1126/science.27726572772657
   PubMed Web of Science ®Google Scholar
• Riordan JR, Rommens JM, Kerem B-S, et al. Identification of the cystic fibrosis gene: cloning and characterization of the complementary DNA. Science. 1989;245:1066–1073. doi:10.1126/science.24759112475911
   PubMed Web of Science ®Google Scholar
• UK Cystic Fibrosis. Registry annual data report 2017. Available from: https://www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-registry/reporting-and-resources. Accessed 316, 2019
   Google Scholar
• Cystic Fibrosis mutation database. Available from: http://www.genet.sickkids.on.ca. Accessed 615, 2019.
   Google Scholar
• Alton EW, Armstrong DK, Ashby D, et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3:684–691. doi:10.1016/S2213-2600(15)00245-326149841
   PubMed Web of Science ®Google Scholar
• Alton EW, Beekman JM, Boyd AC, et al. Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. Thorax. 2017;72(2):137–147. doi:10.1136/thoraxjnl-2016-20840627852956
   PubMed Web of Science ®Google Scholar
• Pedemonte NGL, Lukacs K, Du E, et al. Small-molecule correctors of defective {Delta}F508-CFTR cellular processing identified by high-throughput screening. J Clin Invest. 2005;115(9):2564–2571. doi:10.1172/JCI2489816127463
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Davies J, McElvaney G. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663–1672. doi:10.1056/NEJMoa110518522047557
   PubMed Web of Science ®Google Scholar
• De Boeck K, Munck A, Walker S, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros. 2014;13(6):674–680. doi:10.1016/j.jcf.2014.09.00525266159
   PubMed Web of Science ®Google Scholar
• Guimbellot J, Solomon GM, Baines A, et al. Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J Cyst Fibros. 2019;18(1):102–109. doi:10.1016/j.jcf.2018.04.00429685811
   PubMed Web of Science ®Google Scholar
• Moss RB, Flume PA, Elborn JS, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015;3(7):524–533. doi:10.1016/S2213-2600(15)00201-526070913
   PubMed Web of Science ®Google Scholar
• Flume PA, Liou TG, Borowitz DS. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012;142(3):718–724. doi:10.1378/chest.11-267222383668
   PubMed Web of Science ®Google Scholar
• Wainwright CE, Elborn JS, Ramsey BW, et al. (TRAFFIC study group) lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220–231. doi:10.1056/NEJMoa140954725981758
   PubMed Web of Science ®Google Scholar
• Konstan MW, McKone EF, Moss RB, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017;5(2):107–118. doi:10.1016/S2213-2600(16)30427-128011037
   PubMed Web of Science ®Google Scholar
• Southern KW, Patel S, Sinha IP, Nevitt SJ. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Cochrane Database Syst Rev. 2018;8: Art. No.: CD010966. doi:10.1002/14651858.CD010966.pub2
   PubMed Web of Science ®Google Scholar
• Harbeson SL, Morgan AJ, Liu JF, et al. Altering metabolic profiles of drugs by precision deuteration 2: discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development. J Pharmacol Exp Ther. 2017;362(2):359–367. doi:10.1124/jpet.117.24149728611092
   PubMed Web of Science ®Google Scholar
• McColley SA, Konstan MW, Ramsey BW, et al. Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1. J Cyst Fibros. 2019;18(1):94–101. doi:10.1016/j.jcf.2018.07.01130146268
   PubMed Web of Science ®Google Scholar
• Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol. 2011;46(4):393. doi:10.1002/ppul.v46.420967845
   PubMed Web of Science ®Google Scholar
• Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the cystic fibrosis questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic pseudomonas aeruginosa airway infection. Chest. 2009;135(6):1610–1618. doi:10.1378/chest.08-119019447923
   PubMed Web of Science ®Google Scholar
• Rowe SM, McColley SA, Rietschel E, et al. Lumacaftor/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR. Ann Am Thorac Soc. 2017;14(2):213–219. doi:10.1513/AnnalsATS.201609-689OC27898234
   PubMed Web of Science ®Google Scholar
• Milla CE, Ratjen F, Marigowda G, et al. Lumacaftor/ivacaftor in patients aged 6–11 years with cystic fibrosis and homozygous for F508del-CFTR. Am J Respir Crit Care Med. 2017;195(7):912–920. doi:10.1164/rccm.201701-0150WS27805836
   PubMed Web of Science ®Google Scholar
• Ratjen F, Hug C, Marigowda G, et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2017;5(7):557–567. doi:10.1016/S2213-2600(17)30215-128606620
   PubMed Web of Science ®Google Scholar
• Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014;2(7):527–538. Epub 2014 Jun 24. doi:10.1016/S2213-2600(14)70132-824973281
   PubMed Web of Science ®Google Scholar
• Graeber SY, Dopfer C, Naehrlich L, et al. Effects of lumacaftor-ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in Phe508del homozygous patients with cystic fibrosis. Am J Respir Crit Care Med. 2018;197(11):1433–1442. doi:10.1164/rccm.201710-1983OC29327948
   PubMed Web of Science ®Google Scholar
• McNamara JJ, McColley SA, Marigowda G, et al. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Lancet Respir Med. 2019. doi:10.1016/S2213-2600(18)30460-0
   Web of Science ®Google Scholar
• Davies JC, Cunningham S, Harris WT, et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med. 2016;(2):107–115. doi:10.1016/S2213-2600(15)00545-7
   PubMed Web of Science ®Google Scholar
• Elborn S 1, Ramsey BW, Boyle MP, et al. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respir Med. 2016;(8):617–626. doi:10.1016/S2213-2600(16)30121-727298017
   PubMed Web of Science ®Google Scholar
• Pedersen SS, Jensen-Fangel S, Jeppesen M. Bridging for lung transplantation with lumacaftor/ivacaftor. Bridging for lung transplantation with lumacaftor/ivacaftor. Breathe. 2018;14:e68–e71. doi:10.1183/20734735.01931830131838
   PubMed Web of Science ®Google Scholar
• Murer C, Huber LC, Kurowski T, et al. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial – preliminary results. Swiss Med Wkly. 2018;148:w14593. doi:10.4414/smw.2018.1457529451946
   PubMed Web of Science ®Google Scholar
• Hammond JA, Connett GJ. The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis. Paediatr Respir Rev. 2018;27:16–17. doi:10.1016/j.prrv.2018.05.00829914743
   PubMed Web of Science ®Google Scholar
• Tiddens HA, Donaldson SH, Rosenfeld M, Paré PD. Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively? Pediatr Pulmonol. 2010;45(2):107–117. doi:10.1002/ppul.v45:2
   PubMed Web of Science ®Google Scholar
• Taylor-Cousar JL, Jain M, Barto TL, et al. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. J Cyst Fibros. 2018;17(2):228–235. doi:10.1016/j.jcf.2017.09.01229126871
   PubMed Web of Science ®Google Scholar
• Brokaar E, van Leeuwen M, Leegwater E, et al. Adverse drug reactions and discontinuation rate during the first year on orkambi – the earliest results of the STORM study. J Cyst Fibros. 2019;18(Suppl 1):S130. doi:10.1016/S1569-1993(19)30553-3
   Google Scholar
• Whiting P, Al M, Burgers L, et al. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2014;18:18. doi:10.3310/hta18180
   Web of Science ®Google Scholar
• McColley SA. A safety evaluation of ivacaftor for the treatment of cystic fibrosis. Expert Opin Drug Saf. 2016;15(5):709–715. doi:10.1517/14740338.2016.116566626968005
   PubMed Web of Science ®Google Scholar
• Schneider EK, Azad MA, Han ML, et al. An unlikely pair: the antimicrobial synergy of polymyxin b in combination with the cystic fibrosis transmembrane conductance regulator drugs KALYDECO and ORKAMBI. ACS Infect Dis. 2016;2(7):478–488. doi:10.1021/acsinfecdis.6b0008227626100
   PubMed Web of Science ®Google Scholar
• Keating D, Marigowda G, Burr L, et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med. 2018;379(17):1612–1620. doi:10.1056/NEJMoa180712030334692
   PubMed Web of Science ®Google Scholar
• Berkers G, van Mourik P, Vonk AM, et al. Rectal organoids enable personalized treatment of cystic fibrosis. Cell Rep. 2019;26(7):1701–1708.e3. doi:10.1016/j.celrep.2019.01.06830759382
   PubMed Web of Science ®Google Scholar